Death from gastric cancer ‐ modified ITT analysis · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy probably leads to lower death from gastric cancer ‐ modified ITT analysis compared with control (moderate certainty).
1 finding from 1 review
Death Analysis 1.1 · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in death from all causes ‐ modified ITT analysis compared with control (moderate certainty).
1 finding from 1 review
Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in incidence of oesophageal squamous cell carcinoma ‐ modified ITT… compared with control (moderate certainty).
1 finding from 1 review
Adverse events · healthy asymptomatic H. pylori‐infected individuals
1 finding from 1 review
Intervention not reported
Anxiety · individuals with any cancer at any stage
1 finding from 1 review
Intervention not reported
Depression · individuals with any cancer at any stage
1 finding from 1 review
Intervention not reported
Fatigue · individuals with any cancer at any stage
1 finding from 1 review
Intervention not reported
Emotional distress · individuals with any cancer at any stage
1 finding from 1 review
Intervention not reported
Other outcomes included uncertainty, pain, sexually related symptoms, dyspnoea, and general symptoms. Data for any of these outcomes were not pooled due to considerable heterogeneity across all aspects. Magnitudes of effect were not reported · individuals with any cancer at any stage
1 finding from 1 review
no estimate extracted
2 participants
Very low
Contamination with fluor marker when using gowns · healthcare worker volunteers
1 finding from 1 review
Contamination with fluor marker when using aprons · healthcare worker volunteers
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with dual antiplatelet agent (very low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · Individuals with Hodgkin lymphoma
The intervention probably leads to higher overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · Individuals with Hodgkin lymphoma
It is very uncertain whether the intervention changes progression‐free survival (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events associated with PET ‐ not reported · Individuals with Hodgkin lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (adjusted effect estimate) · Individuals with Hodgkin lymphoma
1 finding from 1 review
Intervention not reported
Progression‐free survival (adjusted effect estimate) · Individuals with Hodgkin lymphoma
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review